CHEK2 and breast cancer: More efforts are needed in multicentric, prospective larger and longer-term dedicated studies for MB, especially to create more robust guidelines for screening in high-risk men no-carriers of BRCA 1–2 mutations (including PTEN, CHEK2, and BARD1 gene mutation carriers and personal or family history of BC, etc.).